For PD-1/PD-L1 inhibitor therapy, cross-immunity of CD8+ T cells to common antigens in skin and tumor tissues may be one of the causes of SJS/TEN, such as BP180, an anchor filament component involved in dermal-epidermal junction (Berner et al., 2019). This evidence concerns the gene CD8A and neoplasm.